

Evaluation of salivary beta-2 microglobulin as HBV proliferation marker in HBS Ag⁺, HBV DNA PCR⁺ and HBV DNA PCR⁻ subjects

Hamidreza Abdolsamadi¹, Peiman Eini², Negin Ronasi¹, Seyed Alireza Kaboli³, Mehrdad Hajiloeei⁴, Abbas MoghimBeigi⁵, Poorandokht Davoudi¹, Fatemeh AhmadiMotemayel^{1,6}, Hamid Mohaghegh Shalmani⁷

¹Department of Oral Medicine, School of Dentistry, Dentistry Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

²Department of Infectious Diseases, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

³Department of Gastroenterology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

⁴Department of Immunology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

⁵Department of Biostatistics, School of Health, Hamadan University of Medical Sciences, Hamadan, Iran

⁶Research Center of Molecular Medicine and Dental Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

⁷Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT

Aim: The aim of this study was to determine the concentration of salivary B₂M as a marker of viral proliferation in HBS Ag⁺, HBV DNA PCR⁺ and Hbs Ag⁺ and HBV DNA PCR⁻ subjects.

Background: Beta-2 microglobulin (B₂M) is responsible for transmission of viral antigens such as Hepatitis B (HBV) on the surface of liver cells as part of an HLA complex.

Patients and methods: In this case control study, 25 PCR⁺ and 2 PCR⁻ patients were included. 5 mL of the saliva sample was obtained from all patients and salivary B₂M level was measured using nephelometer. The data was evaluated by the descriptive, chi-square and t-tests.

Results: 72% of the PCR⁺ patients received medications and in contrast, 85.7% of the patients with PCR⁻ did not take any medication (P<0.001). The average salivary concentration of Beta-2 microglobulin in the PCR⁺ group (5.28 ± 5.45 mg/deciliter) was more than PCR⁻ group (1.51±0.77) and this difference was statistically significant (P=0.003).

Conclusion: the salivary B₂M level can be used as a marker of viral proliferation in patients with hepatitis B.

Keywords: Beta-2 microglobulin, Saliva, Hepatitis B, Virus proliferation marker.

(Please cite as: **Abdolsamadi H, Eini P, Ronasi N, Kaboli SA, Hajiloeei M, MoghimBeigi A, et al. Evaluation of salivary Beta-2 microglobulin as HBV proliferation marker in HBS Ag⁺, HBV DNA PCR⁺ and HBV DNA PCR⁻ subjects. Gastroenterol Hepatol Bed Bench 2013;6(Suppl.1):S105-S111).**

Introduction

Hepatitis means inflammation of the liver and includes wide range of clinical and pathological conditions (1, 2). According to the latest statistics

of World Health Organization (WHO), hepatitis has chronically affected more than 350 million people in the world and is one of the major problems of the health care system (3-5). The infected people are the main source and the main factor of disease transmission (6). According to data from fourth international congress of Hepatitis, Iran is an endemic region of hepatitis B

Received: 15 March 2013 Accepted: 18 June 2013

Reprint or Correspondence: Negin Ronasi, MD.
Department of Oral Medicine, School of Dentistry, Dentistry Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

E-mail: neginjavrose@yahoo.com

with average prevalence of 2.3%. In some regions of country such as Golestan and Sistan-va-Baloochestan provinces, prevalence of the disease reaches 6%. In the meantime, 35% of the Iran population is at the risk of infection with the disease and 3.4% of the population chronically carries hepatitis B virus (7). The main mechanism of damaging the hepatic cells in hepatitis is reaction of the immune system (8). The studies on cellular immune system shows that the presence of HLA antigen and cohesion molecules in hepatocytes level for provision of HBV is the key factor and results in activity of T lymphocytes against HBS Ag and HBe Ag (9,10). There is also direct relationship between HLA-1 of the hepatocytes and inflammation of the hepatic cells in hepatitis B (10). When the person become infected with HBV, the first virologic marker, which can be identified in the serum, saliva and sperm is HBs-Ag within 8-12 weeks after contamination (1, 3). In addition, there is another important and reliable diagnostic test such as HBV DNA using PCR method. Patients with HBV DNA values of more than 20,000 units in milliliter or 100,000 copies in milliliters are at the risk of high infectivity and possible hepatic cirrhosis, hepatic dysfunction and hepatocellular carcinoma (1, 2). B₂M is a single polypeptide chain including 18 amino acids lacking carbohydrate with molecular weight of 11.8 kilodalton, which forms Beta HLA-1 chain. It is located on surface of most nucleated cells and also in most body fluids such as blood, saliva, urine, sperm, cerebrospinal fluid, synovial liquid and milk (11, 12). B₂M is responsible for transmission of viral antigens on the surface of liver cells as a part of the HLA complex (13). Normal concentration of B₂M is 1.5-3 ng/l in serum and 0-0.38 ng/l in the saliva (14). According to the studies on acute hepatitis, stable chronic hepatitis, hepatic cirrhosis and transmitter without symptoms of hepatitis B, a considerable increase of the B₂M concentration in serum has been reported (8, 10).

Unfortunately there is limited information about salivary B₂M serum levels in patients with hepatitis B despite the fact that spitting has some advantages compare to blood drawing. Spit sample is a non-aggressive method, easier to access and the ability to be performed by the patients. Therefore, it seems that salivary B₂M monitoring can be considered as a reliable index to study the disease trend, response to the therapy and follow-up. This issue was one of the goals of this research.

Patients and Methods

In this case control study, the patients who had positive HBS Ag at least for 6 months, and had a PCR test for investigating HBV DNA were included and were referred to Farshchian hospital affiliated with Hamadan University of Medical Sciences. Patients' refusal, the dialysis patients, presence of other systemic diseases and medication intake not related to hepatitis within the past 3 months were the exclusion criteria. After completing other required tests including HbeAg, HbeAb, LFT and HBV DNA, the subjects were treated and they were followed periodically. The samples were collected after taking the informed consent from the participants and their charts were investigated. The cases were selected after investigating 400 patients' charts related to all kinds of hepatitis. 150 cases of hepatitis B subjects were selected of whom 90 of the cases were excluded from the study for different reasons such as lack of PCR result, lack of accurate information and patients' refusal. From all the cases, 60 patients were selected and the saliva samples were taken from 46 patients after coordination and they were referred to the infectious diseases ward. 21 out of 46 subjects were in negative PCR group and 25 subjects were in positive PCR group. HBV DNA of more than 20,000 unit/milliliters or 100,000 copies/milliliters were considered as positive PCR sample and the

lower values were considered as negative PCR (1, 2). Saliva was collected using spitting method (15). All samples were collected in a definite time interval i.e. between 8 and 10 AM and all were taken in winter to have the minimum salivary changes. About 5cc of the saliva was taken using the above method and was immediately placed in ice pack and was transferred to the laboratory. All the samples were kept at -20°C until all were collected. Later, all samples were de-frozen and centrifuged for 10 min at 4°C and with speed of 800 g to separate the squamous cells and cellular debris. 12ml of the centrifuged fluid was used for measuring values of $\beta_2\text{M}$ in the lidded and sterile plastic tubes (falcon) while they were put in the ice. $\beta_2\text{M}$ level was measured with HUMAN MININEPH kit made by Binding site Company, England and with nephelometer method (11,16).

All data were analyzed by SPSS software, version 16 and using descriptive, chi-square and t-tests and value of $P < 0.05$ was considered statistically significant.

Results

In this study, 21 patients with positive HBS Ag and 25 patients with positive HBS Ag and with HBV DNA PCR⁺ were investigated including totally 25 males (54.3%) and (45.7%) females. The ratio of male to female was obtained to be $\frac{1}{2}$, which was not significant in terms of gender ($P=0.86$). The average age of the participants in this study was 86.11 ± 72.35 years and age range was 14-61 years and this difference was not statistically significant ($P=0.48$).

72% of the PCR⁺ patients took medication for the treatment in contrast to 85.7% of the PCR⁻ who did not take any medication ($P < 0.001$). There was a statistically significant difference between PCR⁺ and PCR⁻ groups in concentration of salivary beta-2 microglobulin ($P=0.003$), which is showed in table 1. However, concentration of this index was not significantly different in males and

females ($P=0.572$). Pearson Correlation Coefficient between concentration of salivary Beta-2 microglobulin and age was -0.229 , which was not statistically significant considering $P=0.126$. Considering table 2, results of this study showed that concentration of the salivary Beta-2 microglobulin was significantly high in the patients who received pharmacotherapy compared with the patients who didn't take medication ($P=0.002$).

Table 1. Average concentration of salivary $\beta_2\text{M}$ in patients with HBS Ag⁺ in two PCR⁺ (n=25) and PCR⁻ (n=21) groups

	mean \pm SD	Min	Max	P-value
Concentration $\beta_2\text{M}$				0.003
PCR ⁺	5.28 \pm 5.45	0.76	20.76	
PCR ⁻	1.51 \pm 0.77	0.76	2.43	

Table 2. Mean (\pm standard deviation) concentration of salivary $\beta_2\text{M}$ in patients with HBS Ag⁺ based on the record of medicine taking

	No (%)	Concentration	P-value
medicine taking			0.002
Yes	21 (45.7)	5.6 \pm 5.88	
No	25 (54.3)	1.8 \pm 1.01	

Discussion

HBV-DNA is known as a viral marker in simulation of HBV and has the highest diagnostic value in terms of sensitivity and quantity (1, 2). Negative HBeAg can indicate reduction of the viral simulation but virus simulation and cell proliferation continue in some patients despite HBe-Ab⁺. This status can be due to mutation changes in viral Pre- core area. Therefore, this study tries to use HBV-DNA as a virus proliferation factor (13). There is direct relationship between HLA-1 of hepatocytes and inflammation of hepatic cells in hepatitis B (17, 18). $\beta_2\text{M}$ shows beta HLA-1 chain and is available located on the cellular surface of most nucleated cells and liquids of the body (19). The present study showed increase of $\beta_2\text{M}$ in PCR⁺ group.

β_2 M production increases in response to several factors, such as inflammation, acidosis, therapy with calcitriol and dialysis (12, 16, 20, 21), acute and chronic cirrhosis (13, 23, 22) and in many viral diseases (23, 24), renal disorders (20, 16, 25, 26), autoimmune diseases and lymphoproliferative diseases. This increase is found in plasma cells dyscrasia and all kinds of solid tumors (14, 17, 22, 27, 28). β_2 M is responsible for transmission of viral antigens such as hepatitis B (HBV) on the surface of hepatic cells as a part of the HLA complex. β_2 M can be an index in incidence of the HBV virus. According to performed studies, there is considerable increase of β_2 M in viral acute hepatitis, stable chronic hepatitis (11, 17, 18, 20), hepatic cirrhosis and transmitters without symptoms of hepatitis B (11, 13, 18, 29). Therefore, it seems that increase of serum β_2 M can be an important index in liver inflammatory changes. Some studies about chronic hepatitis B and C indicated serum values of β_2 M (23, 28, 29). In the patients suffering from hepatitis C who were cured with interferon α , it was specified that β_2 M could indicate activity of the disease and effectiveness of the hepatitis treatment (13, 18).

It was also specified that values of β_2 M before and during hepatitis treatment could help predict the therapeutic results (22-24).

Results of this study showed that concentration of β_2 M in the subjects with positive HBSAg and HBV-DNA PCR was higher than of PCR group and indicated that the subjects with hepatitis B had more β_2 M than PCR group in case of higher viral proliferation. In this study, 72% of the PCR patients took medicine (lamivudine and adefovir) and 85.7% of the PCR patients didn't take any medicine and this statistically significant difference ($P < 0.001$) between two groups indicated therapeutic follow-up of the patients and medical team for the PCR subjects. Study of Lapinski (22) on 24 patients with cured chronic hepatitis C introducing β_2 M and INF- γ as the activity index and therapy effectiveness, is

consistent with our study. Elefsiniotis also concluded that there was a specified relationship between β_2 M serum reduction and virologic level of disease in patients with chronic hepatitis and monotherapy with lamivudine (29). HBV-DNA serum is a predictor of virological response of the disease and HBV-DNA quantitative measurement presents good prognostic information but it requires high quality laboratory test. Salivary β_2 M is inexpensive and easy to access and increase of the salivary level of β_2 M in hepatitis B can be a good method for assessment of virus proliferation instead of PCR in serum (17, 24, 29). Akdogum studied the changes in hepatic transaminases, β_2 M and HBV-DNA and stated that values of β_2 M can be effective and applicable for prediction of the therapy results (22). Therefore, salivary concentration of β_2 M in our study was higher in PCR group compared with PCR group despite therapy with medicines other than INF- γ . Yegane used β_2 M for disease monitoring (17). In this study, average serum values of β_2 M in the (symptomatic) patients was higher than the average values in patients without symptoms and also in patients with progression of the disease and this difference was comparable with the present study considering. On the other hand, in a study done by Shayegan, serum β_2 M values in patients with chronic hepatitis B PCR and PCR were compared among 35 healthy subjects. In PCR group, average concentration of β_2 M was higher than PCR and this difference was statistically significant (4). In our study, 72% of the PCR patients received medications and average concentration of salivary Beta-2 microglobulin in PCR was higher than in PCR group regardless of their therapeutic duration.

In 2002, Lapinski announced that concentration of β_2 M was a predictor of the disease activity and response to the therapy among the patients with chronic hepatitis C who were cured with interferon- α . He stated that the patients who received unsuccessful therapy showed increase of

β_2 M level. This result was different compare to the previous studies (13,18), which was due to the hepatic inflammation changes. Results of our study showed increase of β_2 M in the patients after therapy (22).

Cooper has studied 158 serum specimens collected from the patients with CMV, infectious mononucleosis, HSV and VZV in virology section of blood bank. Their study showed an increase of β_2 M value has been affected by different forms of viral infection (24). In patients with AIDS, increase of serum β_2 M occurs in cases that are infected with *Pneumocystis carinii* or sarcoma kaposis. The role of CMV in etiology of sarcoma kaposis can indicate the relationship between CMV and increase of serum β_2 M (24). Elevation of serum β_2 M indicates either the deficiency in glomerular filtration or increase of its production. Increase of β_2 M production is due to effect of the disease on patients' immune system. Previous studies have demonstrated the highest rate of β_2 M at the beginning of acute hepatitis phase. A considerable increase of β_2 M also occurs during rejection of the liver allograft relating to the hepatocytes damage (8, 25). Serum β_2 M values are dependent on age. In this study, patients with active hepatitis C are older than patients with stable β_2 M. Increase of serum β_2 M with aging may be due to dysfunction of the liver; other factors can be explained by factor of age (23, 24). Michelis studied saliva β_2 M in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and hemodialysis (HD) and determined an increase of serum β_2 M value in all of these three groups but salivary β_2 M in HD patients was similar to the values before hemodialysis. Uncontrolled leakage of β_2 M into the saliva in hemodialytic patients is probably due to the absence of relationship between concentration of saliva and serum β_2 M. The excessive and uncontrolled leakage of β_2 M in saliva causes the inappropriate concentration in the saliva, which has no relationship with its main values in the

serum. In contrast, the relationship between serum β_2 M in saliva in CKD patients is strong. Therefore, saliva analysis is a good adjunct method of evaluation of the CKD versus serum study based on the current results (21).

As mentioned before, serum HBV DNA PCR levels presents good diagnostic information but it is an expensive test and requires high quality laboratory equipment. In contrast, it is cheaper and easier to measure serum β_2 M using microparticle enzyme immunoassay technology. Therefore, evaluation of β_2 M saliva level in hepatitis B can be replaced by the assessment of the virus proliferation using PCR method. It is suitable and easy to perform diagnostic method which is cost-effective compared with other methods.

Our study only investigates salivary β_2 M level and its relationship with hepatitis B. The salivary β_2 M in CKD was also assessed which was found to be similar to increase in the saliva. Considering very limited studies on saliva in the future studies, it is better to compare saliva and serum β_2 M rate in the patients to specify advantage of using the saliva and study relationship between virus and enzyme quantity. In addition, it is better to compare the group with hepatitis with the healthy control group in the future studies.

Concentration of β_2 M in positive HBV-DNA is higher than in negative HBV-DNA. Therefore, it seems that it can be considered as an index for virus proliferation.

Acknowledgements

This research project under No. 910219573 is financed and endorsed by Hamadan University of Medical Sciences and we hereby appreciate the research and technology deputy of the university.

References

1. Anderoli TE, Benjumin I, Wing EJ, Editors. Andreoli and Carpenter's Cecil essentials of medicine. New York: W.B. Saunders; p.466-80.

2. Fauci A, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al, Editors. Harrison's principles of internal medicine. 17th edition. New York: McGraw-Hill; 2012. P.2067-88.
3. Itharatana K. Viral hepatitis B infection. Transmission and prevention for dentists. J Dent Assoc Thai 1988;38:180-87. [In Thai]
4. Shaiegan M, Tarabadi FA, AminiKafi-Abadi S, Samiee S, BabaieG, Talebian A. Evaluation of serumic beta-2 microglobulin in HBS Ag+, HBV DNA PCR+ and HBS Ag+, HBV DNA PCR- subjects: as HBV replication marker. J Blood 2006;6:253-58.
5. Kao JH. Diagnosis of hepatitis B virus infection: serological diagnosis of HBV infection. Expert Rev Gastroenterol Hepatol 2008;2:553-62.
6. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006;26:130-41.
7. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B virus infection in iran: a systematic review. Hepat Mon 2008; 8: 281-94.
8. Kieslichová E, Schück O, Smrcková I, Granátová J, Skibová J, Merta D, et al. Liver transplantation and peri-operative changes to renal function. Vnitr Lek 2009;55:1126-34. [In Czech]
9. Tofigi H, Ghorbani M, Akhlaghi M, Yaghmaei A. Incidence of hepatitis B and HIV virus at cadaver of IV drug abusers in Tehran. Acta Medica Iranica 2011; 49: 59-63.
10. Kim BK, Han KH, Ahn SH. Hepatitis B virus serology to predict antiviral response in chronic hepatitis B. Digestion 2011; 84:29-34.
11. Man R-A, Lindermans J, Schalm SW, Kate FJW. β 2Microglobulin and antiviral therapy for chronic hepatitis type B. Antivir Res 1989; 11: 181-90.
12. Geest SA, Markusse HM, Swaak AJG. β 2microglobulin measurements in saliva of patients with primary Sjogren's syndrome: influence of flow. Ann Rheum Dis 1993; 52: 461-63.
13. Malaguarnera M, Restuccia S, Di Fazio I, Zoccolo AM, Trovato BA, Pistone G. Serum β 2microglobulin in Chronic hepatitis C. Digest Dis Sci 1997; 42: 762-66.
14. Drueke TB, Mossy ZA. β 2- microglobulin. Semin Dial 2009; 22: 378-80.
15. Navazesh M, Kumar SK. Measuring salivary flow: challenges and opportunities. J Am Dent Assoc 2008;139:S35-40.
16. Nagler RM. Saliva analysis for monitoring dialysis and renal function. Clin Chem 2008; 54: 1415-17.
17. Yegane S, Revanli M, Taneli F. The role of β 2-microglobulin levels in monitoring chronic Hepatitis B. Tohoku J Exp Med 2004; 203: 53-57.
18. Westral R, Norkrans G, Weiland O, Schvarcz R, Fuchs D. Lymphocyte subsets and β 2-microglobulin expression in chronic hepatitis C/non A, non B: effects of interferon-alpha treatment. Clin Exp Immunol 1992; 87: 340-45.
19. Shabana AHM. Expression of beta-2 microglobulin by normal, benign and malignant oral epithelia. Saudi Dent J 1991; 1: 92-98.
20. Malaguarnera M, Di Fazio I, Ferlito L, Pistone G, Laurino A, Vinci E, et al. Increase of serum beta2-microglobulin in patients affected by HCV correlated hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2000;12:937-39.
21. Michelis R, Sela S, Ben-Zvi I, Nagler RM. Salivary β 2-microglobulin analysis in chronic kidney disease and hemodialyzed patients. Blood Purifi 2008; 25: 505-509.
22. Lapinski TW, Kot A, Prokopowicz D. Concentration of β 2microglobulin and percentage of CD4 lymphocytes in peripheral blood in patients with chronic HCV infection during IFN- α therapy. Med Sci Monit 2002; 8: 538-42.
23. Akdogan M, Senturk H, Mert A, Tabak F, Ozbay G. Acute exacerbation during interferon alfa treatment of chronic hepatitis B: frequency and relation to serum β 2microglobulin levels. J Gastroenterol 2003; 38: 456-70.
24. Cooper EH, Forbes MA, Hambling MH. Serum β 2-microglobulin and C reactive protein concentrations in viral infections. J Clin Pathol 1984; 37: 1140-43.
25. Tramonti G, Cipollini I, Annichiarico C, Lorusso P, Panicucci E, Mariani G, et al. Creatinine clearance, cystatin C, beta2-microglobulin and TATI as markers of renal function in patients with proteinuria. J Nephrol 2012;25:976-82.
26. Wada T, Miyata T, Sakai H, Kurokawa K. Beta2-microglobulin and renal bone disease. Perit Dial Int 1999;19:S413-16.
27. Suzuki K, Suk PJ, Hong C, Imaizumi S, Tagami K. Exercise-induced liver beta2-microglobulin expression is related to lower IgG clearance in the blood. Brain Behav Immun 2007;21:946-52.
28. Qu Y, Gao CF, Zhou K, Zhao YP, Xu MY, Lu LG. Serum N-glycomic markers in combination with

panels improves the diagnosis of chronic hepatitis B. *Ann Hepatol* 2012;11:202-12.

29. Elefsiniotis IS, Scarneas N, Glynou I, Pantazis KD, Kada H, Mavriagiannis C. Serum beta-2 microglobuli levels in hepatitis B e antigen-negative

chronic hepatitis B patients under long term lamivudine monotherapy: relationship with virological breakthrough. *Can J Gastroenterol* 2004; 18: 307-13.